🇺🇸 FDA
Pipeline program

Praliciguat

AKB-1973-CI-0001

Phase 2 small_molecule active

Quick answer

Praliciguat for Focal Segmental Glomerulosclerosis is a Phase 2 program (small_molecule) at Akebia Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Akebia Therapeutics
Indication
Focal Segmental Glomerulosclerosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials